Market capitalization | $3.07m |
Enterprise Value | $-1.63m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.18 |
P/B ratio (TTM) P/B ratio | 0.48 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-8.67m |
Free Cash Flow (TTM) Free Cash Flow | $-9.06m |
Cash position | $4.70m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
1 Analyst has issued a forecast Phio Pharmaceuticals Corp.:
1 Analyst has issued a forecast Phio Pharmaceuticals Corp.:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.13 -0.13 |
32%
32%
|
|
EBITDA | -8.55 -8.55 |
30%
30%
|
EBIT (Operating Income) EBIT | -8.67 -8.67 |
30%
30%
|
Net Profit | -8.68 -8.68 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
Head office | United States |
CEO | Robert Bitterman |
Employees | 9 |
Founded | 2011 |
Website | www.phiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.